December 1, 2020 Abivax completes recruitment of ABX464 phase 2b induction study in ulcerative colitis
October 12, 2020 CARMAT is granted € 13M in national innovation funding to conduct the EFICAS study in France
September 2, 2020 Abivax reports long-lasting two-year efficacy and safety data from ABX464 ulcerative colitis Phase 2A maintenance study
July 31, 2020 MEDEOR, Truffle Capital's new BioMedTech Fund, qualified by institutional investors through the Tibi committee
June 23, 2020 Abivax provides business update on most recent achievements and announces positive results of annual ordinary and extraordinary general meeting